We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

47 hedge funds and large institutions have $16.3M invested in Orchard Therapeutics plc American Depositary Shares in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

0% more funds holding

Funds holding: 47 → 47 (0)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

34% less capital invested

Capital invested by funds: $24.7M → $16.3M (-$8.38M)

Holders
47
Holders Change
–
Holders Change %
0%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
10
Reduced
10
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Mariner
Mariner
Kansas
+$279K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$46K
3
FA
Forefront Analytics
Pennsylvania
+$28.7K
4
Jane Street
Jane Street
New York
+$13.1K
5
Goldman Sachs
Goldman Sachs
New York
+$8.94K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$1.67M
2
BlackRock
BlackRock
New York
-$356K
3
Renaissance Technologies
Renaissance Technologies
New York
-$306K
4
UOC
UBS O'Connor
Illinois
-$216K
5
Verition Fund Management
Verition Fund Management
Connecticut
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$3.19M – – –
Federated Hermes
2
Federated Hermes
Pennsylvania
$3.12M – – –
CA
3
CHI Advisors
New York
$2.96M – – –
Temasek Holdings
4
Temasek Holdings
Singapore
$1.6M – – –
DM
5
Deerfield Management
New York
$1.17M -$1.67M -378,771 -55%
Citadel Advisors
6
Citadel Advisors
Florida
$851K +$1.76K +398 +0.2%
TCM
7
Tang Capital Management
California
$742K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$683K -$306K -69,316 -27%
AG
9
Artal Group
Luxembourg
$669K – – –
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$445K +$46K +10,401 +9%
Mariner
11
Mariner
Kansas
$234K +$279K +63,098 New
Millennium Management
12
Millennium Management
New York
$119K -$17.4K -3,935 -11%
Morgan Stanley
13
Morgan Stanley
New York
$108K -$2.68K -607 -2%
CAM
14
Cormorant Asset Management
Massachusetts
$95K – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$81K -$2.38K -538 -2%
FA
16
Forefront Analytics
Pennsylvania
$61.2K +$28.7K +6,485 +65%
Jane Street
17
Jane Street
New York
$28.1K +$13.1K +2,969 +65%
AFG
18
Allegheny Financial Group
Pennsylvania
$10.7K +$5.3K +1,200 +72%
TSS
19
Two Sigma Securities
New York
$9.41K +$5.1K +1,153 +83%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$9K – – –
Two Sigma Investments
21
Two Sigma Investments
New York
$8.13K -$6.49K -1,468 -40%
BCV
22
Banque Cantonale Vaudoise
Switzerland
$8K – – –
CS
23
Cannell & Spears
New York
$7.84K – – –
Two Sigma Advisers
24
Two Sigma Advisers
New York
$7.83K +$707 +160 +8%
Goldman Sachs
25
Goldman Sachs
New York
$7.5K +$8.94K +2,022 New
1
2 3

ORTX Hedge Fund Activity: Q4 2022 in Review

47 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q4 2022, worth a combined $16.3M — down 34% from $24.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ORTX positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.

The largest buyer was Mariner, opening a new position worth an estimated $279K. The largest seller was Deerfield Management, cutting an estimated $1.67M.

  • 47 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $16.3M of Orchard Therapeutics plc American Depositary Shares stock for Q4 2022, down 34% quarter-over-quarter.
  • 8 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q4 2022 and 6 closed out, a net change of +2 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q4 2022 was Mariner, an estimated $279K added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q4 2022 was Deerfield Management, an estimated $1.67M sold.

Based on aggregated 13F filings for Q4 2022.